IBDEI1M6 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27385,1,3,0)
 ;;=3^Proteinuria,Unspec
 ;;^UTILITY(U,$J,358.3,27385,1,4,0)
 ;;=4^R80.9
 ;;^UTILITY(U,$J,358.3,27385,2)
 ;;=^5019599
 ;;^UTILITY(U,$J,358.3,27386,0)
 ;;=D51.8^^106^1352^2
 ;;^UTILITY(U,$J,358.3,27386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27386,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,27386,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,27386,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,27387,0)
 ;;=D52.9^^106^1352^1
 ;;^UTILITY(U,$J,358.3,27387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27387,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,27387,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,27387,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,27388,0)
 ;;=I10.^^106^1353^12
 ;;^UTILITY(U,$J,358.3,27388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27388,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,27388,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,27388,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,27389,0)
 ;;=I15.0^^106^1353^13
 ;;^UTILITY(U,$J,358.3,27389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27389,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,27389,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,27389,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,27390,0)
 ;;=I13.11^^106^1353^8
 ;;^UTILITY(U,$J,358.3,27390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27390,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,27390,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,27390,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,27391,0)
 ;;=I13.2^^106^1353^7
 ;;^UTILITY(U,$J,358.3,27391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27391,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,27391,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,27391,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,27392,0)
 ;;=I70.1^^106^1353^3
 ;;^UTILITY(U,$J,358.3,27392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27392,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,27392,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,27392,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,27393,0)
 ;;=I77.3^^106^1353^2
 ;;^UTILITY(U,$J,358.3,27393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27393,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,27393,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,27393,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,27394,0)
 ;;=E26.02^^106^1353^5
 ;;^UTILITY(U,$J,358.3,27394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27394,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,27394,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,27394,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,27395,0)
 ;;=I12.9^^106^1353^14
 ;;^UTILITY(U,$J,358.3,27395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27395,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,27395,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,27395,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,27396,0)
 ;;=I12.0^^106^1353^15
 ;;^UTILITY(U,$J,358.3,27396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27396,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,27396,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,27396,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,27397,0)
 ;;=I13.0^^106^1353^6
 ;;^UTILITY(U,$J,358.3,27397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27397,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,27397,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,27397,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,27398,0)
 ;;=I13.10^^106^1353^9
